These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30227312)

  • 21. Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis.
    Boullosa-Lale S; González-Freire L; Martínez-Martínez L; Crespo-Diz C
    Farm Hosp; 2020 Dec; 45(2):73-76. PubMed ID: 33709887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.
    Smoot K; Spinelli KJ; Stuchiner T; Lucas L; Chen C; Grote L; Baraban E; Kresa-Reahl K; Cohan S
    Mult Scler; 2018 Jun; 24(7):942-950. PubMed ID: 28537110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature.
    Dello Russo C; Scott KA; Pirmohamed M
    Pharmacol Ther; 2021 Mar; 219():107710. PubMed ID: 33091427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.
    Sainz de la Maza S; Sabin Muñoz J; Pilo de la Fuente B; Thuissard I; Andreu-Vázquez C; Galán Sánchez-Seco V; Salgado-Cámara P; Costa-Frossard L; Monreal E; Ayuso-Peralta L; García-Vasco L; García-Domínguez JM; Martínez-Ginés ML; Muñoz Fernández C; Díaz-Díaz J; Oreja-Guevara C; Gómez-Moreno M; Martín H; Rubio-Flores L; Blasco MR; Villar-Guimerans LM; Aladro Y;
    Mult Scler Relat Disord; 2022 Mar; 59():103669. PubMed ID: 35150979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with multiple sclerosis.
    Borrelli S; Mathias A; Goff GL; Pasquier RD; Théaudin M; Pot C
    Mult Scler Relat Disord; 2022 Jul; 63():103887. PubMed ID: 35636269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report.
    Harmel P; Schlunk F; Harms L
    Mult Scler; 2018 Jul; 24(8):1131-1133. PubMed ID: 29708444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-life persistence and tolerability with dimethyl fumarate.
    Sejbaek T; Nybo M; Petersen T; Illes Z
    Mult Scler Relat Disord; 2018 Aug; 24():42-46. PubMed ID: 29906666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
    Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
    Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
    Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
    Front Immunol; 2018; 9():1097. PubMed ID: 29896193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
    Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Herpes encephalitis during natalizumab treatment in multiple sclerosis.
    Kwiatkowski A; Gallois J; Bilbault N; Calais G; Mackowiak A; Hautecoeur P
    Mult Scler; 2012 Jun; 18(6):909-11. PubMed ID: 22048950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.
    Mirabella M; Prosperini L; Lucchini M; Boffa L; Borriello G; Buscarinu MC; Centonze D; Cortese A; De Fino C; De Giglio L; Elia G; Fantozzi R; Ferraro E; Francia A; Galgani S; Gasperini C; Haggiag S; Landi D; Marfia GA; Millefiorini E; Monteleone F; Nociti V; Salvetti M; Sgarlata E; Pozzilli C
    CNS Drugs; 2018 Oct; 32(10):963-970. PubMed ID: 30022464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
    Kogel AK; Gold R; Schneider R
    J Neurol; 2021 Nov; 268(11):4374-4375. PubMed ID: 34175973
    [No Abstract]   [Full Text] [Related]  

  • 35. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate.
    Wood CH; Robertson NP; Htet ZM; Tallantyre EC
    Mult Scler Relat Disord; 2022 Feb; 58():103492. PubMed ID: 35066268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study.
    Roar M; Nielsen ARH; Berg JM; Sirakov G; Stilund M; Schäfer J; Ratzer R; Frederiksen J; Asgari N; Ashna SN; Jensen HB; Kant M; Theódorsdóttir Á; Illes Z; Sellebjerg F; Magyari M; Schlosser LM; Nordborg H; Wergeland S; Sejbaek T
    Mult Scler Relat Disord; 2023 Dec; 80():105127. PubMed ID: 37956521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of dimethyl fumarate on lymphocyte subsets.
    Berkovich R; Weiner LP
    Mult Scler Relat Disord; 2015 Jul; 4(4):339-41. PubMed ID: 26195053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dimethyl fumarate-associated transient bone marrow oedema syndrome.
    Triplett J; Vijayan S; Prince R; Kermode A
    Mult Scler; 2019 May; 25(6):876-879. PubMed ID: 30051766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
    Dorman E; Kansal AR; Sarda S
    J Med Econ; 2015; 18(12):1085-91. PubMed ID: 26390149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
    J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.